Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone ResistancePatrick N. A. Harris, David L. Paterson, Elda Righi et al.|JAMA|2018Cited by 761
Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO StudyAndrew Henderson, Bassam Alalwan, David L. Paterson et al.|Clinical Infectious Diseases|2020Cited by 155
Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase–Producing <i>Enterobacter</i> spp, <i>Citrobacter freundii</i>, <i>Morganella morganii</i>, <i>Providencia</i> spp, or <i>Serratia marcescens</i>: A Pilot Multicenter Randomized Controlled Trial (MERINO-2)Adam G. Stewart, Gabriel Yan, David L. Paterson et al.|Open Forum Infectious Diseases|2021Cited by 91
Whole genome analysis of cephalosporin-resistant Escherichia coli from bloodstream infections in Australia, New Zealand and Singapore: high prevalence of CMY-2 producers and ST131 carrying blaCTX-M-15 and blaCTX-M-27Patrick N. A. Harris, Tony M. Korman, Nouri L. Ben Zakour et al.|Journal of Antimicrobial Chemotherapy|2017Cited by 82
Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trialPatrick N. A. Harris, David L. Paterson, Anton Y. Peleg et al.|Trials|2015Cited by 73